Markov模型于20世紀(jì)80年代用于醫(yī)學(xué)領(lǐng)域，目前已成為藥物經(jīng)濟(jì)學(xué)評(píng)價(jià)中最常用的方法之一，且前景廣闊。國(guó)內(nèi)利用Markov模型進(jìn)行藥物經(jīng)濟(jì)學(xué)評(píng)價(jià)雖然相比于國(guó)外起步較晚，但發(fā)展速度不斷加快，差距日漸縮小，評(píng)價(jià)方案逐步實(shí)現(xiàn)正規(guī)化。查閱近5年國(guó)內(nèi)外相關(guān)文獻(xiàn)，圍繞模型建立與參數(shù)設(shè)定、設(shè)立對(duì)照、不確定性分析以及評(píng)價(jià)結(jié)果這4個(gè)基本流程，簡(jiǎn)述國(guó)內(nèi)外學(xué)者利用Markov模型進(jìn)行藥物經(jīng)濟(jì)學(xué)評(píng)價(jià)的研究進(jìn)展，并指明該方法的不足之處。

The Markov model was used in the medicinal field in the 1980s. It has become one of the most commonly used method in pharmaco-economics and it also has broad prospects. The use of Markov model in pharmaco-economics in China started later than aboard. However, the pace of development continues to be accelerated and the gap is shrinking. The evaluation program is being gradually normalized. To search the related literature in the last five years and around modeling establishment, the parameter settings, the uncertainty analysis, and the evaluation results of these four basic processes, the research progress of domestic and foreign scholars who use Markov model for pharmaco-economics evaluation are summarized and the shortcomings of this method are indicated.